The results of this evaluation demonstrate that in the
treatment of PACS in the community setting, BUCCOLAM
is dominant (reduced costs and greater QALYs)
over current care in each of the countries modelled. This
is the case despite differences in the patterns of care,
local costs and substantial data limitations. Comprehensive
sensitivity analyses show that model outputs are robust
for all countries.
A key conclusion of the evidence generated for the
model was that the availability of BUCCOLAM prefilled
syringes is likely to increase both the willingness and
ability of parents and carers to administer treatment in
the community. This improves the effectiveness of the
treatment of PACS, resulting in better outcomes compared
with rectal diazepam. As a result of these improved
outcomes, BUCCOLAM was estimated to consistently
reduce ambulance call-out and hospitalisation rates for the
treatment of PACS across a range of healthcare systems.
The capacity for BUCCOLAM to reduce resource use
and expenditure following a seizure episode has been demonstrated
across a range of European healthcare systems.
Although the expected savings may be considered small in
relation to the total international economic burden of
treating epilepsy, this does not diminish the improved outcomes
experienced by the individual and the substantial
savings that can be achieved compared with current care.